TY - JOUR
T1 - Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy
AU - Acosta, Andres
AU - Camilleri, Michael
AU - Shin, Andrea
AU - Vazquez-Roque, Maria I.
AU - Iturrino, Johanna
AU - Burton, Duane
AU - O'Neill, Jessica
AU - Eckert, Deborah
AU - Zinsmeister, Alan R.
N1 - Funding Information:
Funding This research and Dr Camilleri were funded by National Institutes of Health (NIH) RO1-DK67071 ; medication used for this study was provided by VIVUS; no other support was provided. This study was supported by CCaTS grant #UL1-TR000135 from NIH (Endoscopy, Physiology and Imaging Core; and Nursing Core in the Mayo Clinical Research Unit).
Publisher Copyright:
© 2015 AGA Institute.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background & Aims Weight loss after pharmacotherapy varies greatly. We aimed to examine associations of quantitative gastrointestinal and psychological traits with obesity, and to validate the ability of these traits to predict responses of obese individuals to pharmacotherapy. Methods In a prospective study, we measured gastric emptying of solids and liquids, fasting and postprandial gastric volume, satiation by nutrient drink test (volume to fullness and maximal tolerated volume), satiety after an ad libitum buffet meal, gastrointestinal hormones, and psychological traits in 328 normal-weight, overweight, or obese adults. We also analyzed data from 181 previously studied adults to assess associations betwecen a subset of traits with body mass index and waist circumference. Latent dimensions associated with overweight or obesity were appraised by principal component analyses. We performed a proof of concept, placebo-controlled trial of extended-release phentermine and topiramate in 24 patients to validate associations between quantitative traits and response to weight-loss therapy. Results In the prospective study, obesity was associated with fasting gastric volume (P =.03), accelerated gastric emptying (P <.001 for solids and P =.011 for liquids), lower postprandial levels of peptide tyrosine tyrosine (P =.003), and higher postprandial levels of glucagon-like peptide 1 (P <.001). In a combined analysis of data from all studies, obesity was associated with higher volume to fullness (n = 509; P =.038) and satiety with abnormal waist circumference (n = 271; P =.016). Principal component analysis identified latent dimensions that accounted for approximately 81% of the variation among overweight and obese subjects, including satiety or satiation (21%), gastric motility (14%), psychological factors (13%), and gastric sensorimotor factors (11%). The combination of phentermine and topiramate caused significant weight loss, slowed gastric emptying, and decreased calorie intake; weight loss in response to phentermine and topiramate was significantly associated with calorie intake at the prior satiety test. Conclusions Quantitative traits are associated with high body mass index; they can distinguish obesity phenotypes and, in a proof of concept clinical trial, predicted response to pharmacotherapy for obesity. ClinicalTrials.gov Number: NCT01834404.
AB - Background & Aims Weight loss after pharmacotherapy varies greatly. We aimed to examine associations of quantitative gastrointestinal and psychological traits with obesity, and to validate the ability of these traits to predict responses of obese individuals to pharmacotherapy. Methods In a prospective study, we measured gastric emptying of solids and liquids, fasting and postprandial gastric volume, satiation by nutrient drink test (volume to fullness and maximal tolerated volume), satiety after an ad libitum buffet meal, gastrointestinal hormones, and psychological traits in 328 normal-weight, overweight, or obese adults. We also analyzed data from 181 previously studied adults to assess associations betwecen a subset of traits with body mass index and waist circumference. Latent dimensions associated with overweight or obesity were appraised by principal component analyses. We performed a proof of concept, placebo-controlled trial of extended-release phentermine and topiramate in 24 patients to validate associations between quantitative traits and response to weight-loss therapy. Results In the prospective study, obesity was associated with fasting gastric volume (P =.03), accelerated gastric emptying (P <.001 for solids and P =.011 for liquids), lower postprandial levels of peptide tyrosine tyrosine (P =.003), and higher postprandial levels of glucagon-like peptide 1 (P <.001). In a combined analysis of data from all studies, obesity was associated with higher volume to fullness (n = 509; P =.038) and satiety with abnormal waist circumference (n = 271; P =.016). Principal component analysis identified latent dimensions that accounted for approximately 81% of the variation among overweight and obese subjects, including satiety or satiation (21%), gastric motility (14%), psychological factors (13%), and gastric sensorimotor factors (11%). The combination of phentermine and topiramate caused significant weight loss, slowed gastric emptying, and decreased calorie intake; weight loss in response to phentermine and topiramate was significantly associated with calorie intake at the prior satiety test. Conclusions Quantitative traits are associated with high body mass index; they can distinguish obesity phenotypes and, in a proof of concept clinical trial, predicted response to pharmacotherapy for obesity. ClinicalTrials.gov Number: NCT01834404.
KW - BMI
KW - Incretin
KW - Phentermine
KW - Satiety
KW - Topiramate
UR - http://www.scopus.com/inward/record.url?scp=84923871070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923871070&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2014.11.020
DO - 10.1053/j.gastro.2014.11.020
M3 - Article
C2 - 25486131
AN - SCOPUS:84923871070
SN - 0016-5085
VL - 148
SP - 537-546.e4
JO - Gastroenterology
JF - Gastroenterology
IS - 3
ER -